Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galmed PharmaceuticalsFRA:GPH 29 EV-to-FCF is 1.53 as of Jul. 16, 2026, which is 31% below its 10-year median of 2.21. GuruFocus rates FRA:GPH with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 334 Biotechnology companies, Galmed Pharmaceuticals ranks better than 74.25% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Galmed Pharmaceuticals's Enterprise Value is €-10.10 Mil.
Galmed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-6.60 Mil. Therefore, Galmed Pharmaceuticals's EV-to-FCF for today is 1.53.
The historical rank and industry rank for Galmed Pharmaceuticals's EV-to-FCF or its related term are showing as below:
FRA:GPH'
s EV-to-FCF Range Over the Past 10 Years
Min: -19.46 Med: 2.21 Max: 7.42
Current: 1.5
During the past 13 years, the highest EV-to-FCF of Galmed Pharmaceuticals was 7.42. The lowest was -19.46. And the median was 2.21.
FRA:GPH's EV-to-FCF is ranked better than 74.25% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs FRA:GPH: 1.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Galmed Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Galmed Pharmaceuticals's share price for today is €2.736.
Galmed Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.864.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Galmed Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galmed Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Galmed Pharmaceuticals's EV-to-FCF falls into.
Galmed Pharmaceuticals's current Enterprise Value is €-10.10 Mil.
Galmed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galmed Pharmaceuticals (FRA:GPH) has a EV-to-FCF of 1.53 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Galmed Pharmaceuticals and its competitors. This is 31% below median its historical median of 2.21. According to the industry distribution chart, Galmed Pharmaceuticals ranks #86 out of 334 companies in the Biotechnology industry, placing it in the top 25.7%.
Is Galmed Pharmaceuticals' EV-to-FCF too high?
Galmed Pharmaceuticals' current EV-to-FCF of 1.53 is 31% below median its 10-year median of 2.21. The Biotechnology industry median EV-to-FCF is 15.69. Galmed Pharmaceuticals' value of 1.53 is 90.2% below this industry median. Based on the distribution chart, Galmed Pharmaceuticals ranks #86 out of 334 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Galmed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' EV-to-FCF compare to FBLG and SXTP?
According to the Biotechnology industry distribution chart, Galmed Pharmaceuticals ranks #86 out of 334 companies for EV-to-FCF. This puts Galmed Pharmaceuticals in the upper half of its industry. The industry median EV-to-FCF is 15.69. Galmed Pharmaceuticals' value of 1.53 is 90.2% below this benchmark. While the company's 10-year median is 2.21 vs. the industry median of 15.69, Galmed Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galmed Pharmaceuticals's current EV-to-FCF of 1.53 is 90.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Galmed Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galmed Pharmaceuticals's current EV-to-FCF is 1.53, which is 31% below median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (FRA:GPH) has a current EV-to-FCF of 1.53. The current EV-to-FCF is 1.53, which is 31% below median its 10-year median of 2.21 and 90.2% below the Biotechnology industry median of 15.69. Galmed Pharmaceuticals' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Galmed Pharmaceuticals (FRA:GPH), the current EV-to-FCF is 1.53 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
29GF Score
Get the complete analysis for FRA:GPH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GPH has been successfully added to your 
